EGFR and colorectal carcinoma: Throughout the last decade,significant advancement in our understanding of the molecular mechanisms ofmetastatic CRC has been made.Anti-EGFR monoclonal antibodies approved for use in the metastatic setting havebroadened the therapeutic armamentarium in the treatment of metastatic CRC.